Un apoyo modesto al predominio de la clínica | 09 FEB 15

Biomarcadores en el diagnóstico de sepsis

La evidencia muestra que los biomarcadores actuales tienen un rendimiento diagnóstico sólo moderado y un papel limitado en la clínica.
Autor/a: Anthony S McLean, professor of intensive care medicine, Benjamin Tang, associate professor of intensive care medicine, Stephen J Huang, associate professor and principal research fellow, intensive car Fuente: BMJ 2015; 350 doi: http://dx.doi.org/10.1136/bmj.h254 Investigating sepsis with biomarkers
INDICE:  1. Desarrollo | 2. Referencias
Referencias
  1. Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA.Sepsis syndrome: a valid clinical entity. Methyl-prednislone Severe Sepsis Study Group. Crit Care Med1989;17:389-93.
  2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med2013;39:165-228.
  3. Bryan C, Morris AM, Tomlinson G, Detsky AS. Does this adult patient with suspected bacteremia require blood culture? JAMA2012;308:502-11.
  4. Paran Y, Yablecovitch D, Choshen G, Zeitlin I. C-reactive protein velocity to distinguish febrile bacterial infections from non-bacterial febrile illnesses in the emergency department. Crit Care2009;13:R50.
  5. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis2004;39:206-17.
  6. Phypers B, Pierce JM. Lactate physiology in health and disease. Contin Educ Anaesth Crit Care Pain2006;6:128-32.
 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

AAIP RNBD
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2023